AbbVie to Acquire Apogee Therapeutics for $10.9B to Bolster Immunology Pipeline
AbbVie (ABBV) announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal. The acquisition aims to bolster AbbVie's pipeline of candidates for inflammatory and immunological diseases, reinforcing its leadership in the immunology space.
Key Numbers
AbbVie (ABBV) announced the acquisition of clinical-stage biotech Apogee Therapeutics for $10.9 billion in cash, as reported by Barron's. The deal is designed to strengthen AbbVie's pipeline of candidates for inflammatory and immunological diseases, further solidifying its position in the immunology market.
Deal Details
| Item | Detail |
|---|---|
| Total Value | $10.9 billion in cash |
| Target | Apogee Therapeutics (clinical-stage) |
| Therapeutic Area | Inflammatory and immunological diseases |
| Payment Method | All cash |
| Expected Close | Not yet announced |
Rationale
AbbVie aims to enhance its immunology portfolio, a key growth driver. Apogee's pipeline includes promising clinical-stage candidates that could offset potential revenue declines from patent expirations on some of AbbVie's current blockbuster drugs.
Regulatory Hurdles
The deal is expected to face antitrust review in the U.S. and Europe. Given AbbVie's significant market share in immunology, regulators may require divestitures or other remedies to maintain competition.
Stock Impact
The acquisition may pressure AbbVie's stock in the near term due to the large cash outlay, but it strengthens long-term growth prospects. Investors will watch for details on financing and the impact on earnings per share.
Frequently Asked Questions
Found this useful? Share it